TIANJIN PHARM DA REN TANG GRP (T14) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of TIANJIN PHARM DA REN TANG GRP $1.63, price $2.49, upside -34.5%, quality 73 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch TIANJIN PHARM DA REN TANG GRP for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range $0.6364 – $3.66 · fair‑value band $1.40 – $2.44 · the $2.49 price screens above the $1.63 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow TIANJIN PHARM DA REN TANG GRP in your weekly email
Every Wednesday you see whether TIANJIN PHARM DA REN TANG GRP is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China.
Show more
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmological, tumor, chronic, and other diseases, as well as tonic drugs. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited and changed its name to Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited in May 2022. The company was founded in 1915 and is based in Tianjin, the People's Republic of China.
Stock analysis
TIANJIN PHARM DA REN TANG GRP (T14) currently trades at $2.49, while our model-based Fair Value estimate is $1.63, 34.5% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $5.22 per share, and 9 of the 22 models we run sit above the $2.49 price.
Bear case: the Asset-Based group reads lowest at $0.7000, and 13 of the 22 models stay below the price. Evidence for this calculation is medium.
Scenario range: $1.40 (bear) to $2.44 (bull), the price of $2.49 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 73/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
TIANJIN PHARM DA REN TANG GRP reported revenue of 4.9B CNY in FY2025 versus 6.9B CNY in FY2021, a compound −8.1%/yr. Reported net income was 2.1B CNY in FY2025, compounding +29.0%/yr from FY2021.
Key figures
Market cap $3.6B · P/E ratio 6.6 · P/S ratio 2.86 · EPS (TTM) $0.4200 · Net margin 43.3% · Return on equity 27.5% · Return on assets (EBIT) 7.7% · Operating margin 33.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (medium confidence).
What moves the price
The share trades about 32% below its 52-week high and 279% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −35%, T14 screens richer than that median.
Fair Value models
Bear $1.40Fair Value $1.63Bull $2.44
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.60/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.3%
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+44.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+44.2%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.9% → 20%
2025 sits 116% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−3.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −4.8% a year for the price.
Compare TIANJIN PHARM DA REN TANG GRP with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 599 stocks
Beats the industry median on 8/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score73 · Top 25%
Fair Value upside−43.9% · Below median
Profitability
Return on equity (TTM)27.5% · Top 25%
Return on assets5.9% · Above median
Net margin (TTM)43.8% · Top 25%
Operating margin (TTM)33.0% · Top 25%
Growth and dividend
Revenue growth4.1% · Below median
Dividend yield (TTM)25.1% · Top 25%
Balance sheet
Debt / equity0.03× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (TTM)6.6× · Cheapest 25%
P/B3.37× · Priciest 25%
P/S (TTM)4.81× · Priciest 25%
P/FCF69.9× · Priciest 25%
EV/EBITDA20.5× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 17
FUTURE (revenue growth)21· sector 24
PAST (return on equity)100· sector 27
HEALTH (low debt)98· sector 96
DIVIDEND (yield)0· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "TIANJIN PHARM DA REN TANG GRP Fair Value". https://www.fairvalue-calculator.com/stock/T14
Frequently asked questions
Is TIANJIN PHARM DA REN TANG GRP (T14) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $1.63 versus a price of $2.49, about −35% upside (overvalued).
What is the fair value of T14?
Our model-based fair value for TIANJIN PHARM DA REN TANG GRP is $1.63 (as of Sep 27, 2026), built from audited fundamentals. The current price: $2.49.
What is the quality score of T14?
TIANJIN PHARM DA REN TANG GRP has a Quality Score of 73/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for TIANJIN PHARM DA REN TANG GRP (T14)?
Our model-based price target is the fair value of $1.63 (as of Sep 27, 2026) from 22 valuation models. Cautious scenario $1.40, optimistic scenario $2.44. It is a calculation from audited fundamentals, not an analyst target.
What is the TIANJIN PHARM DA REN TANG GRP stock forecast for 2026?
Our models put fair value at $1.63, about −35% upside versus a price of $2.49 (overvalued). Cautious scenario $1.40, optimistic scenario $2.44. The calculation is refreshed regularly with new filings.
What is the revenue of TIANJIN PHARM DA REN TANG GRP (T14)?
TIANJIN PHARM DA REN TANG GRP reported trailing-twelve-month revenue of about 5.0B CNY (latest available figure, as of Sep 27, 2026).
What growth is priced into TIANJIN PHARM DA REN TANG GRP (T14)?
For today's price to be fair in a discounted-cash-flow model, TIANJIN PHARM DA REN TANG GRP would have to grow free cash flow by -3.2 % per year for five years (discount rate 8.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -5.7 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of T14 use?
Our models discount TIANJIN PHARM DA REN TANG GRP at 8.5 %: a base by market capitalisation (mid), damped by beta 0.58, country premium for Singapore. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For TIANJIN PHARM DA REN TANG GRP that is -3.2 % per year a year over ten years, using the same discount rate (8.5 %) and the same formula as our fair value.
How much growth has TIANJIN PHARM DA REN TANG GRP (T14) delivered so far?
Over the past 5 years revenue at TIANJIN PHARM DA REN TANG GRP grew -5.7 % a year. The price currently implies -3.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of TIANJIN PHARM DA REN TANG GRP (T14) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into TIANJIN PHARM DA REN TANG GRP (-3.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of TIANJIN PHARM DA REN TANG GRP (T14)?
The free-cash-flow yield on the price is 6.58 %: that much free cash flow TIANJIN PHARM DA REN TANG GRP produces per unit of market value. When it exceeds the discount rate of our models (8.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of TIANJIN PHARM DA REN TANG GRP (T14)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For TIANJIN PHARM DA REN TANG GRP it is $1.63 per share (as of Sep 27, 2026), against a price of $2.49. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is TIANJIN PHARM DA REN TANG GRP stock overvalued or undervalued in 2026?
As of Sep 27, 2026, T14 trades above its calculated fair value: price $2.49, fair value $1.63, a gap of about −35% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of T14?
No. The price is what the market pays today ($2.49); the fair value is what the company's own numbers justify ($1.63). For TIANJIN PHARM DA REN TANG GRP the two are $0.8600 per share apart. That gap is exactly why we show both numbers side by side.
How much is TIANJIN PHARM DA REN TANG GRP worth?
The market values TIANJIN PHARM DA REN TANG GRP at about $3.6B (market capitalisation, as of Sep 27, 2026). Per share that is $2.49; our models calculate a fair value of $1.63 per share.
What do the bullish and bearish scenarios say about T14?
Our models span a range for TIANJIN PHARM DA REN TANG GRP: cautious scenario $1.40, base $1.63, optimistic $2.44 per share (as of Sep 27, 2026, price $2.49). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of T14?
TIANJIN PHARM DA REN TANG GRP trades at a price-to-earnings ratio of 6.6 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $1.63 is built from several models across several years. Other multiples: P/B 3.4, P/S 4.8, EV/EBITDA 20.5.
How solid is the balance sheet of TIANJIN PHARM DA REN TANG GRP (T14)?
Balance-sheet figures for TIANJIN PHARM DA REN TANG GRP (as of Sep 27, 2026): return on equity 27.5%, debt of 0.03 per unit of equity. They feed the Quality Score of 73/100, which measures business quality independently of the share price.
How far is T14 from its 52-week high?
TIANJIN PHARM DA REN TANG GRP trades at $2.49, about 32% below its 52-week high of $3.66 and 279% above the low of $0.6578 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $1.63 is for.
Which stocks are comparable to TIANJIN PHARM DA REN TANG GRP?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is TIANJIN PHARM DA REN TANG GRP stock attractive at the current price?
The data as of Sep 27, 2026: price $2.49, calculated fair value $1.63 (−35%), Quality Score 73/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of T14 calculated?
We run TIANJIN PHARM DA REN TANG GRP through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.63, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. TIANJIN PHARM DA REN TANG GRP itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of TIANJIN PHARM DA REN TANG GRP (T14)?
The closing price on Oct 2, 2026 was $2.49. Our model-based fair value is $1.63, about −35% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with TIANJIN PHARM DA REN TANG GRP right now?
A high-quality business (quality 73/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case ($2.44). The favourable scenario is already priced in.
Key figures of TIANJIN PHARM DA REN TANG GRP
How large is the market capitalisation of TIANJIN PHARM DA REN TANG GRP (T14)?
The market capitalisation of TIANJIN PHARM DA REN TANG GRP is $3.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of TIANJIN PHARM DA REN TANG GRP (T14)?
The price-to-sales ratio of TIANJIN PHARM DA REN TANG GRP is 2.86 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of TIANJIN PHARM DA REN TANG GRP (T14)?
Earnings per share at TIANJIN PHARM DA REN TANG GRP are $0.4200 (price ÷ EPS = P/E 6.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of TIANJIN PHARM DA REN TANG GRP (T14)?
The net margin of TIANJIN PHARM DA REN TANG GRP is 43.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of TIANJIN PHARM DA REN TANG GRP (T14)?
The return on equity (ROE) of TIANJIN PHARM DA REN TANG GRP is 27.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of TIANJIN PHARM DA REN TANG GRP (T14)?
On an EBIT basis the return on assets of TIANJIN PHARM DA REN TANG GRP is 7.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of TIANJIN PHARM DA REN TANG GRP (T14)?
The operating margin of TIANJIN PHARM DA REN TANG GRP is 33.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at TIANJIN PHARM DA REN TANG GRP (T14)?
Revenue at TIANJIN PHARM DA REN TANG GRP is growing +4.1% versus a year earlier (3y avg −15.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at TIANJIN PHARM DA REN TANG GRP (T14)?
Earnings per share at TIANJIN PHARM DA REN TANG GRP are growing +12.2% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch TIANJIN PHARM DA REN TANG GRP in the live analysis
One click puts TIANJIN PHARM DA REN TANG GRP on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
